Your browser is no longer supported. Please, upgrade your browser.
APTX Aptinyx Inc. daily Stock Chart
Aptinyx Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own2.80% Shs Outstand32.89M Perf Week2.55%
Market Cap185.50M Forward P/E- EPS next Y-2.38 Insider Trans- Shs Float27.41M Perf Month-5.69%
Income-46.40M PEG- EPS next Q-0.50 Inst Own74.10% Short Float2.37% Perf Quarter-77.89%
Sales6.70M P/S27.69 EPS this Y-107.20% Inst Trans-2.92% Short Ratio2.09 Perf Half Y-75.42%
Book/sh4.87 P/B1.16 EPS next Y-2.10% ROA- Target Price19.33 Perf Year-
Cash/sh5.03 P/C1.12 EPS next 5Y- ROE- 52W Range4.70 - 32.25 Perf YTD-65.90%
Dividend- P/FCF- EPS past 5Y- ROI81.20% 52W High-82.51% Beta-
Dividend %- Quick Ratio21.80 Sales past 5Y- Gross Margin- 52W Low19.97% ATR0.78
Employees64 Current Ratio21.80 Sales Q/Q-25.00% Oper. Margin- RSI (14)23.22 Volatility4.43% 6.61%
OptionableNo Debt/Eq0.00 EPS Q/Q-70.50% Profit Margin- Rel Volume0.27 Prev Close5.70
ShortableYes LT Debt/Eq0.00 EarningsFeb 12 Payout- Avg Volume311.14K Price5.64
Recom2.00 SMA203.03% SMA50-57.85% SMA200-73.35% Volume84,768 Change-1.05%
Jan-17-19Downgrade JP Morgan Overweight → Neutral
Nov-15-18Initiated Cantor Fitzgerald Overweight $40
Jul-16-18Initiated Leerink Partners Outperform $35
Jul-16-18Initiated JP Morgan Overweight $30
Jan-17-19 08:06AM  The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US Benzinga -9.87%
Jan-16-19 04:37PM  Biotech Play Aptinyx Tanks After Drug Trial Fails -66.46%
04:34PM  Why Ford Motor, Snap, and Aptinyx Slumped Today Motley Fool
11:46AM  Here's Why Aptinyx Got Crushed Today Motley Fool
09:19AM  Aptinyx stock falls 67% after phase 2 trial fails to meet primary endpoint MarketWatch
07:27AM  Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy GlobeNewswire
Jan-02-19 08:07AM  Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-20-18 12:50PM  Should You Take Comfort From Insider Transactions At Aptinyx Inc. (NASDAQ:APTX)? Simply Wall St. -18.62%
Dec-11-18 08:27AM  Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacologys Annual Meeting GlobeNewswire
Dec-05-18 08:07AM  Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-03-18 07:27AM  Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia GlobeNewswire -10.00%
Nov-21-18 07:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Nov-13-18 07:27AM  Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Nov-12-18 07:07AM  Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans GlobeNewswire
Nov-01-18 07:27AM  Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy GlobeNewswire
Oct-29-18 08:07AM  Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience GlobeNewswire
Sep-25-18 04:01PM  Aptinyx to Present at Cantor Fitzgerald Global Healthcare Conference GlobeNewswire +7.84%
Sep-14-18 08:07AM  Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pains 17th World Congress on Pain GlobeNewswire
Aug-21-18 06:35AM  Aptinyx Presents Preclinical Data from Fast-Track Designated PTSD Program at Military Health System Research Symposium GlobeNewswire
Aug-14-18 06:27AM  Aptinyx Reports Second Quarter 2018 Financial and Business Results GlobeNewswire
Aug-02-18 08:00AM  Aptinyx Initiates Phase 1 Study of NYX-458 GlobeNewswire
Jun-25-18 05:18PM  Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 10:01PM  [$$] Eidos Therapeutics Goes Public, Joining Biotech IPO Flurry The Wall Street Journal
08:41PM  Aptinyx Announces Pricing of Initial Public Offering PR Newswire
Jun-17-18 04:22PM  The IPO Outlook For The Week Of June 18: Pharma, Pharma And More Pharma Benzinga
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.